Nodify Lung® testing consists of two blood-based proteomic tests, the Nodify CDT® and Nodify XL2® tests, designed to help providers quickly and confidently decipher the risk of malignancy of a lung nodule.
NEWS! Biodesix Named to Inc. Magazine's 2024 "Best Workplaces"
Awarding Excellence in Company Culture
Access fast, reliable, and actionable biological insights with our genomic and proteomic tests to gain a deeper understanding of each patient’s disease state, help expedite diagnosis, and guide confident treatment decisions.
Nodify Lung® testing consists of two blood-based proteomic tests, the Nodify CDT® and Nodify XL2® tests, designed to help providers quickly and confidently decipher the risk of malignancy of a lung nodule.
IQLung Treatment Guidance testing consists of the GeneStrat® targeted test, the GeneStrat NGS® genomic test and the VeriStrat® proteomic test for a broader view of each patient's disease state, with results in 3 business days.* IQLung testing empowers care teams with a testing strategy for any stage of non-small cell lung cancer (NSCLC) and delivers timely biological insights to help expedite personalized treatment decisions.
Capitalize on our scientific rigor and established track record of successful partnerships to meet all your research needs and expedite the diagnostic development process from biomarker discovery to commercialization.
Our breadth of biomarker discovery and assay development services helps our partners to better identify the right patient for the right therapy.
Navigate the clinical trial process for therapeutics with proven solutions, including sample management, data analytics, and quality and regulatory services.
Our companion diagnostic development services arm biopharma partners with solutions to help overcome the challenges and risks associated identifying the right patient for the right therapy in clinical development and in the commercial arena.
*3 business days represents the average turnaround time for testing, individual test turnaround times may vary.